M.Shankaranarayana RaoB
Using next-generation RNA-seq sequencing technology, they confirmed that GHK-Cu modulates the expression of 4,231 genes , of which 2,861 are upregulated and 1,370 are downregulated
Clinical Evidence Several clinical trials and studies underscore the cardiovascular benefits of GLP-1 receptor agonists: SUSTAIN-6 Trial : This pivotal trial demonstrated a significant reduction in major adverse cardiovascular events (MACE) among patients treated with GLP-1 compared to placebo
Glutathione stands at the intersection of metabolism, insulin resistance, and long-term complications
20 How results (e.g., weight loss, glycemic control, etc.) and tolerability (i.e., side effects) compare to current FDA-approved GLP1 and GLP1/GIP receptor agonists remain to be seen
Pro Tip: Use daily, morning and night